NoGeneST™ Anti-EpCAM Aptamer, aEpCAM aptamer-1 sodium

Name: NoGeneST™ Anti-EpCAM Aptamer, aEpCAM aptamer-1 sodium
SKU: NRYF-0625-HZ55
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ55]

A DNA aptamer that specifically targets the cancer stem cell and tumor-associated antigen, EpCAM.

Target:: EPCAM

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is a synthetic single-stranded DNA aptamer engineered to bind with high specificity and affinity to the Epithelial Cell Adhesion Molecule (EpCAM). As EpCAM is widely overexpressed on the surface of circulating tumor cells (CTCs) and cancer stem cells in many epithelial cancers, this aptamer functions as a high-value molecular probe for cancer cell detection, isolation, diagnostic imaging, and targeted drug delivery.

Type

DNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

EPCAM

Full Name

Epithelial Cell Adhesion Molecule

Alternative Names

Epithelial Cell Adhesion Molecule; CD326; TACSTD1 (Tumor-associated calcium signal transducer 1); TROP1

Gene ID

4072

Uniprot ID

P16422

Target Overview

Epithelial Cell Adhesion Molecule (EpCAM) is a transmembrane glycoprotein that functions in cell-to-cell adhesion, proliferation, and signaling. While its expression is typically limited in most healthy epithelial tissues, EpCAM is one of the most frequently and highly overexpressed tumor-associated antigens across a wide variety of carcinomas. Its prevalence on cancer stem cells and circulating tumor cells makes EpCAM a critical biomarker and a prime target for the development of novel cancer-specific therapies and diagnostics.

Publications